|
1
|
Syrios J, Banerjee S and Kaye SB: Advanced
epithelial ovarian cancer: From standard chemotherapy to promising
molecular pathway targets - where are we now? Anticancer Res.
34:2069–2077. 2014.PubMed/NCBI
|
|
2
|
Siegel R, Ward E, Brawley O and Jemal A:
Cancer statistics, 2011: The impact of eliminating socioeconomic
and racial disparities on premature cancer deaths. CA Cancer J
Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
McGuire WP, Hoskins WJ, Brady MF, Kucera
PR, Partridge EE, Look KY, Clarke-Pearson DL and Davidson M:
Cyclophosphamide and cisplatin compared with paclitaxel and
cisplatin in patients with stage III and stage IV ovarian cancer. N
Engl J Med. 334:1–6. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sherman-Baust CA, Becker KG, Iii WH Wood,
Zhang Y and Morin PJ: Gene expression and pathway analysis of
ovarian cancer cells selected for resistance to cisplatin,
paclitaxel, or doxorubicin. J Ovarian Res. 4:212011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Szakács G, Paterson JK, Ludwig JA,
Booth-Genthe C and Gottesman MM: Targeting multidrug resistance in
cancer. Nat Rev Drug Discov. 5:219–234. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gottesman MM, Fojo T and Bates SE:
Multidrug resistance in cancer: Role of ATP-dependent transporters.
Nat Rev Cancer. 2:48–58. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Markman M: Combination versus sequential
cytotoxic chemotherapy in recurrent ovarian cancer: Time for an
evidence-based comparison. Gynecol Oncol. 118:6–7. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Theodoropoulou M and Stalla GK:
Somatostatin receptors: From signaling to clinical practice. Front
Neuroendocrinol. 34:228–252. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Watt HL, Kharmate G and Kumar U: Biology
of somatostatin in breast cancer. Mol Cell Endocrinol. 286:251–261.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yano T, Radulovic S, Osuga Y, Kugu K,
Yoshikawa H, Taketani Y and Schally AV: Inhibition of human
epithelial ovarian cancer cell growth in vitro by somatostatin
analog RC-160. Oncology 59 (Suppl 1). 45–49. 2000.
|
|
11
|
Pyronnet S, Bousquet C, Najib S, Azar R,
Laklai H and Susini C: Antitumor effects of somatostatin. Mol Cell
Endocrinol. 286:230–237. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Robbins RJ: Somatostatin and cancer.
Metabolism 45 (Suppl 1). 98–100. 1996.
|
|
13
|
Susini C and Buscail L: Rationale for the
use of somatostatin analogs as antitumor agents. Ann Oncol.
17:1733–1742. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Oberg K: Cancer: Antitumor effects of
octreotide LAR, a somatostatin analog. Nat Rev Endocrinol.
6:188–189. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Halmos G, Sun B, Schally AV, Hebert F and
Nagy A: Human ovarian cancers express somatostatin receptors. J
Clin Endocrinol Metab. 85:3509–3512. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jones RH, Reubi JC, Millan D and Vasey P:
Octreotide: An active agent in epithelial ovarian carcinoma? Lancet
Oncol. 5:251–253. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Barnett P: Somatostatin and somatostatin
receptor physiology. Endocrine. 20:255–264. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Annaratone L, Volante M, Asioli S, Rangel
N and Bussolati G: Characterization of neuroendocrine tumors of the
pancreas by real-time quantitative polymerase chain reaction. A
methodological approach. Endocr Pathol. 24:83–91. 2013. View Article : Google Scholar
|
|
19
|
Pawlikowski M: The incidence of
somatostatin receptors in human neoplasms in the light of ex
vivo-in vitro studies. Endokrynol Pol. 57:238–243. 2006.(in
Polish). PubMed/NCBI
|
|
20
|
Murphy E, Prommer EE, Mihalyo M and
Wilcock A: Octreotide. J Pain Symptom Manage. 40:142–148. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hua YP, Yin XY, Peng BG, Li SQ, Lai JM,
Liang HZ and Liang LJ: Mechanisms and influence of
octreotide-induced regulation of somatostatin receptor 2 on
hepatocellular carcinoma. Chemotherapy. 55:312–320. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shen Y, Ren M, Shi Y, Zhang Y and Cai Y:
Octreotide enhances the sensitivity of the SKOV3/DDP ovarian cancer
cell line to cisplatin chemotherapy in vitro. Exp Ther Med.
2:1171–1176. 2011.PubMed/NCBI
|
|
23
|
Shen Y, Ren ML, Shi YH, Zhang YX and Cai
YL: Octreotide is the novel alternative for chemosensitivity
enhancement of ovarian cancer cells SKOV3/DDP to cisplatin in vitro
and in nude mice in vivo. Eur J Gynaecol Oncol. 33:584–590.
2012.PubMed/NCBI
|
|
24
|
Chu JJ, Chen KD, Lin YL, Fei CY, Chiang
AS, Chiang CD and Lai YK: Taxol induces concomitant
hyperphosphorylation and reorganization of vimentin intermediate
filaments in 9L rat brain tumor cells. J Cell Biochem. 68:472–483.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Horwitz SB: Mechanism of action of taxol.
Trends Pharmacol Sci. 13:134–136. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Huang CM, Wu YT and Chen ST: Targeting
delivery of paclitaxel into tumor cells via somatostatin receptor
endocytosis. Chem Biol. 7:453–461. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sun ML, Wei JM, Wang XW, Li L, Wang P, Li
M and Yi CH: Paclitaxel-octreotide conjugates inhibit growth of
human non-small cell lung cancer cells in vitro. Exp Oncol.
29:186–191. 2007.PubMed/NCBI
|
|
28
|
Shen H, Hu D, Du J, Wang X, Liu Y, Wang Y,
Wei JM, Ma D, Wang P and Li L: Paclitaxel-octreotide conjugates in
tumor growth inhibition of A549 human non-small cell lung cancer
xenografted into nude mice. Eur J Pharmacol. 601:23–29. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shen Y, Ren ML, Feng X, Cai YL, Gao YX and
Xu Q: An evidence in vitro for the influence of bisphenol A on
uterine leiomyoma. Eur J Obstet Gynecol Reprod Biol. 178:80–83.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lukyanova NY: Characteristics of
homocysteine-induced multidrug resistance of human MCF-7 breast
cancer cells and human A2780 ovarian cancer cells. Exp Oncol.
32:10–14. 2010.PubMed/NCBI
|
|
31
|
Schöndorf T, Kurbacher CM, Göhring UJ,
Benz C, Becker M, Sartorius J, Kolhagen H, Mallman P and Neumann R:
Induction of MDR1-gene expression by antineoplastic agents in
ovarian cancer cell lines. Anticancer Res. 22:2199–2203.
2002.PubMed/NCBI
|
|
32
|
Ebos JM and Kerbel RS: Antiangiogenic
therapy: Impact on invasion, disease progression, and metastasis.
Nat Rev Clin Oncol. 8:210–221. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Akiyama K, Ohga N, Hida Y, Kawamoto T,
Sadamoto Y, Ishikawa S, Maishi N, Akino T, Kondoh M, Matsuda A, et
al: Tumor endothelial cells acquire drug resistance by MDR1
up-regulation via VEGF signaling in tumor microenvironment. Am J
Pathol. 180:1283–1293. 2012. View Article : Google Scholar : PubMed/NCBI
|
